Literature DB >> 1365323

Kalinin is abnormally expressed in epithelial basement membranes of Herlitz's junctional epidermolysis bullosa patients.

G Meneguzzi1, M P Marinkovich, D Aberdam, A Pisani, R Burgeson, J P Ortonne.   

Abstract

Kalinin is an extracellular adhesion molecule specific to epithelial basement membranes (BM) identified as a component of anchoring filaments of hemidesmosomes. This heterotrimeric protein is synthesized by cultured normal human keratinocytes and is involved in cell attachment. In indirect immunofluorescence studies, the epidermal BM of patients with junctional epidermolysis bullosa (JEB) of Herlitz's type were found not to be reactive with the anti-kalinin monoclonal antibodies ka146 and K140 and displayed a decreased immunoreactivity to two anti-kalinin antibodies cross-reacting with K-laminin, an anchoring filament component recently described. The intrinsic defect of JEB keratinocytes in the synthesis of kalinin was further documented by indirect immunofluorescence on in vitro cultures of these cells. In non-Herlitz JEB patients, staining of BM was constantly detected. Impairment of expression of kalinin correlated with the lack of reactivity to the monoclonal antibody GB3, which detects the BM component nicein/BM600. These results clearly demonstrate a defect of kalinin expression in epithelial basement membranes of Herlitz JEB patients and suggest that kalinin may play a role in the pathogenesis of the disease. Further studies are in progress to define possible relationships between kalinin and nicein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365323     DOI: 10.1111/j.1600-0625.1992.tb00080.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  18 in total

1.  Complex formation of the laminin-5 gamma2 chain and large unspliced tenascin-C in oral squamous cell carcinoma in vitro and in situ: implications for sequential modulation of extracellular matrix in the invasive tumor front.

Authors:  Marcus Franz; Torsten Hansen; Petra Richter; Laura Borsi; Frank-D Böhmer; Peter Hyckel; Peter Schleier; Detlef Katenkamp; Luciano Zardi; Hartwig Kosmehl; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2005-12-13       Impact factor: 4.304

Review 2.  Keratin gene mutations in human skin disease.

Authors:  H P Stevens; M H Rustin
Journal:  Postgrad Med J       Date:  1994-11       Impact factor: 2.401

3.  Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.

Authors:  David T Woodley; Jon Cogan; Yingping Hou; Chao Lyu; M Peter Marinkovich; Douglas Keene; Mei Chen
Journal:  J Clin Invest       Date:  2017-07-10       Impact factor: 14.808

4.  Assignment of mouse nicein genes to chromosomes 1 and 18.

Authors:  D Aberdam; M F Galliano; M G Mattei; A Pisani-Spadafora; J P Ortonne; G Meneguzzi
Journal:  Mamm Genome       Date:  1994-04       Impact factor: 2.957

Review 5.  The genetics of human skin disease.

Authors:  Gina M DeStefano; Angela M Christiano
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

6.  Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids.

Authors:  G Giannelli; A Pozzi; W G Stetler-Stevenson; H A Gardner; V Quaranta
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 7.  The molecular basis for inherited bullous diseases.

Authors:  B P Korge; T Krieg
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

Review 8.  Oral manifestations in the epidermolysis bullosa spectrum.

Authors:  J Timothy Wright
Journal:  Dermatol Clin       Date:  2010-01       Impact factor: 3.478

9.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

Review 10.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.